ライフサイエンスコーパス: de novo pathway

1 nine different organisms to form a ten-step de novo pathway.

2 ucleotide triphosphate pools produced by the de novo pathway.

3 trioles have an activity that suppresses the de novo pathway.

4 o regulate the expression or activity of the de novo pathway.

5 ge pathway of ceramide formation and not the de novo pathway.

6 to occur primarily due to activation of the de novo pathway.

7 eramide in LNCaP cells is independent of the de novo pathway.

8 f DHFR and/or other enzymes along the purine de novo pathway.

9 s PGC1alpha deficiency or AKI attenuates the de novo pathway.

10 ucleotide, two members of the Preiss-Handler/de novo pathways.

11 the gene that encodes the third step in the de novo pathway, 3-dehydroquinate dehydratase (DHQ), was

12 y, the pentose phosphate pathway, the purine de novo pathway, amino acids, and neurological disorder-

13 80% of GDP-mannose synthesis comes from the de novo pathway and 20% from the salvage pathway.

14 eaction sits at the branch point between the de novo pathway and the salvage pathway, and has been sh

15 ays in hemopoietic and other cells that lack de novo pathways and are the route of cellular uptake fo

16 on of AT2 receptor induces the activation of de novo pathway, and a metabolite of this pathway, possi

17 lls cannot synthesize GDP-fucose through the de novo pathway, and lack fucosylated glycans, although

18 ineate two main pathways to hypermutation: a de novo pathway associated with constitutional defects i

19 ition of intracellular PA generation through de novo pathways attenuates sepsis-induced acute lung in

20 which the salvage pathway and Preiss-Handler/de novo pathways can exchange intermediates in mammalian

21 However, the regulation of the de novo pathway compared with the salvage pathway is not

22 Mutants in the de novo pathway died upon removal of exogenous nicotinam

23 ibitor of DHODH (rate-limiting enzyme in the de novo pathway) diminishes uridine-5'-phosphate (UMP) p

24 the context of synthetic biology applied to de novo pathway discovery and in systems biology to disc

25 phosphate (dCTP) can be produced both by the de novo pathway (DNP) and by the nucleoside salvage path

26 es mediating ceramide generation through the de novo pathway (e.g. serine palmitoyltransferase) and v

27 y of modular pathway screening to facilitate de novo pathway engineering.

28 ased activity of PDX3 as well as of the B(6) de novo pathway enzyme PDX1, correlating with increased

29 ite complementation." First, the trypanosome de novo pathway enzymes GDP-mannose dehydratase (GMD) an

30 vided evidence to support the existence of a de novo pathway for acetate production derived from pyru

31 the FX locus, which encodes an enzyme in the de novo pathway for GDP-fucose synthesis, exhibit a virt

32 ho1Delta/Delta) eliminates PS and blocks the de novo pathway for PE biosynthesis.

33 idylate synthase (TYMS), which catalyses the de novo pathway for production of deoxythymidine monopho

34 phenolate mofetil (MMF), an inhibitor of the de novo pathway for purine biosynthesis, decreases rejec

35 n of glycinamide ribonucleotide (GAR) in the de novo pathway for purine biosynthesis.

36 at reveals a DMG selective dependency on the de novo pathway for pyrimidine biosynthesis.

37 The first acylation step in the de novo pathway for TAG synthesis is catalyzed by glycer

38 athway, which provides an alternative to the de novo pathway for the biosynthesis of purine nucleotid

39 Biochemical assays of the de novo pathway for the synthesis of GDP-L-fucose indica

40 NAD biosynthesis, remarkably, they have one de novo pathway gene, nadC, encoding quinolinate phospho

41 reased expression of salvage and some of the de novo pathway genes was observed in both the pdx3 and

42 ittle change in expression of the vitamin B6 de novo pathway genes, but significant increases in expr

43 oxylase enzymes that convert PS to PE in the de novo pathway, has diminished PE levels like those of

44 While PLP can be synthesized by a de novo pathway in bacteria and plants, most higher orga

45 reduction in fatty acids synthesized by the de novo pathway in L2 MECs of bitransgenic versus contro

46 1) and endogenous ceramide generated via the de novo pathway in regulating this mechanism.

47 an evolutionary conserved activation of the de novo pathway in response to heat shock.

48 le for sphingolipids synthesized through the de novo pathway in T(H)17 cell development.

49 pids and specifically those generated in the de novo pathway in the cell cycle arrest response to hea

50 hetic pathways in different cell states: the de novo pathway in the pluripotent state, and the salvag

51 e nicotinic acid to yield the Preiss-Handler/de novo pathway intermediate NaMN, with in vivo small mo

52 oss-talk between phospholipid remodeling and de novo pathways involves ubiquitin-lysosomal processing

53 de synthesis through the ceramide synthase 2 de novo pathway is regulated by UPR kinase Perk.

54 hosphates generated from receptor-linked and de novo pathways is crucial to the maintenance of approp

55 This de novo pathway leads to the formation of a random numbe

56 causes marked decreases in the production of de novo pathway metabolites, in direct contrast to delet

57 cidal effect as sudden NAD starvation of the de novo pathway mutant in both actively growing and nonr

58 roceramide desaturase as a key enzyme in the de novo pathway of ceramide generation was investigated

59 IPS) catalyzes the first step of the unique, de novo pathway of inositol biosynthesis.

60 rmine that HCMV promotes the activity in the de novo pathway of phosphatidylcholine (PC) synthesis.

61 of ceramide was blocked by inhibitors of the de novo pathway of SL synthesis, beta-chloro-L-alanine a

62 The de novo pathway of sphingolipid synthesis has been ident

63 d other pathways that play a role in adenine de-novo pathway regulation.

64 ication synthesis occurs exclusively through de novo pathways, relying on lipoyl synthesis/transfer e

65 rine nucleotide biosynthesis, mutants in the de novo pathway that disable the feedback inhibition of

66 dicating that most GDP-fucose is formed by a de novo pathway that involves the bioconversion of GDP-m

67 ose isomerase occupies a key position on the de novo pathway to GDP-mannose from glucose, just before

68 deoxyribonucleotides, and represent the only de novo pathway to provide DNA building blocks.

69 ne (d3-PtdCho)--a metabolite produced in the de novo pathway via choline-derived methyl groups.

70 The GDP-Fuc de novo pathway, which requires the action of GDP-mannos

71 OASS produces L-cysteine via a de novo pathway while CBS participates in the reverse tr

72 modifying natural pathways and establishing de novo pathways with enzymes from a variety of organism

73 osynthesized in this autotroph either by the de novo pathway, with chorismate as an intermediate, or